<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Thrombocytopenia | BB</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Thrombocytopenia simply means having a lower-than-normal number of platelets circulating in the blood (typically defined as &lt;150,000/µL or &lt;150 x 109/L). Platelets are our tiny “first responders”...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Thrombocytopenia | BB">
<meta property="og:type" content="book">
<meta property="og:description" content="Thrombocytopenia simply means having a lower-than-normal number of platelets circulating in the blood (typically defined as &lt;150,000/µL or &lt;150 x 109/L). Platelets are our tiny “first responders”...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Thrombocytopenia | BB">
<meta name="twitter:description" content="Thrombocytopenia simply means having a lower-than-normal number of platelets circulating in the blood (typically defined as &lt;150,000/µL or &lt;150 x 109/L). Platelets are our tiny “first responders”...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><link rel="icon" type="image/png" href="imgs/favicon.png">
<meta name="google-adsense-account" content="ca-pub-1344282930858290">
<script async src="https://www.googletagmanager.com/gtag/js?id=G-JERRQQFPF4"></script><script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-JERRQQFPF4');
    </script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
<link rel="stylesheet" href="toc.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Blood Bank</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li><a class="" href="content-areas.html">Content Areas</a></li>
<li><a class="" href="author.html">Author</a></li>
<li><a class="" href="ascp-boc.html">ASCP BOC</a></li>
<li><a class="" href="reading-list.html">Reading List</a></li>
<li class="book-part">Blood Products</li>
<li><a class="" href="donors.html">Donors</a></li>
<li><a class="" href="qualification.html">Qualification</a></li>
<li><a class="" href="processing.html">Processing</a></li>
<li><a class="" href="adverse-reactions-1.html">Adverse Reactions</a></li>
<li><a class="" href="special-donations-1.html">Special Donations</a></li>
<li><a class="" href="processing-1.html">Processing</a></li>
<li><a class="" href="fda-aabb-requirements.html">FDA, AABB Requirements</a></li>
<li><a class="" href="testing.html">Testing</a></li>
<li><a class="" href="labeling.html">Labeling</a></li>
<li><a class="" href="storage.html">Storage</a></li>
<li><a class="" href="anticoagulantsadditives.html">Anticoagulants/Additives</a></li>
<li><a class="" href="temperature-requirements.html">Temperature Requirements</a></li>
<li><a class="" href="transportation.html">Transportation</a></li>
<li><a class="" href="stored-products.html">Stored Products</a></li>
<li><a class="" href="expiration.html">Expiration</a></li>
<li><a class="" href="blood-components.html">Blood Components</a></li>
<li><a class="" href="red-blood-cells.html">Red Blood Cells</a></li>
<li><a class="" href="cryoprecipitated-ahf.html">Cryoprecipitated AHF</a></li>
<li><a class="" href="platelets.html">Platelets</a></li>
<li><a class="" href="plasma.html">Plasma</a></li>
<li><a class="" href="granulocytes.html">Granulocytes</a></li>
<li><a class="" href="wbc-reduced-components.html">WBC-Reduced Components</a></li>
<li><a class="" href="frozendeglycerolized-rbcs.html">Frozen/Deglycerolized RBCs</a></li>
<li><a class="" href="apheresis-products.html">Apheresis Products</a></li>
<li><a class="" href="fractionation-products.html">Fractionation Products</a></li>
<li><a class="" href="whole-blood.html">Whole Blood</a></li>
<li><a class="" href="washed-rbcs.html">Washed RBCs</a></li>
<li><a class="" href="rejuvenated-rbcs.html">Rejuvenated RBCs</a></li>
<li><a class="" href="irradiated-components.html">Irradiated Components</a></li>
<li><a class="" href="hematopoietic-progenitors.html">Hematopoietic Progenitors</a></li>
<li><a class="" href="blood-component-qc.html">Blood Component QC</a></li>
<li class="book-part">Blood Group Systems</li>
<li><a class="" href="genetics.html">Genetics</a></li>
<li><a class="" href="basic.html">Basic</a></li>
<li><a class="" href="molecular.html">Molecular</a></li>
<li><a class="" href="blood-group-inheritance.html">Blood Group Inheritance</a></li>
<li><a class="" href="biochemistryantigens.html">Biochemistry/Antigens</a></li>
<li><a class="" href="abo.html">ABO</a></li>
<li><a class="" href="lewis.html">Lewis</a></li>
<li><a class="" href="rh.html">Rh</a></li>
<li><a class="" href="mns.html">MNS</a></li>
<li><a class="" href="p1pkglobosidep.html">P1PK/Globoside(P)</a></li>
<li><a class="" href="ii.html">Ii</a></li>
<li><a class="" href="kell.html">Kell</a></li>
<li><a class="" href="kidd.html">Kidd</a></li>
<li><a class="" href="duffy.html">Duffy</a></li>
<li><a class="" href="lutheran.html">Lutheran</a></li>
<li><a class="" href="other-blood-groups.html">Other Blood Groups</a></li>
<li><a class="" href="high-prevalence-antigens.html">High Prevalence Antigens</a></li>
<li><a class="" href="low-prevalence-antigens.html">Low Prevalence Antigens</a></li>
<li><a class="" href="hla.html">HLA</a></li>
<li><a class="" href="platelet-specific.html">Platelet-Specific</a></li>
<li><a class="" href="granulocyte-specific.html">Granulocyte-Specific</a></li>
<li><a class="" href="role-of-blood-groups-in-transfusion.html">Role of Blood Groups in Transfusion</a></li>
<li><a class="" href="immunogenicity.html">Immunogenicity</a></li>
<li><a class="" href="antigen-prevalence.html">Antigen Prevalence</a></li>
<li class="book-part">Immunology &amp; Physiology</li>
<li><a class="" href="immunology.html">Immunology</a></li>
<li><a class="" href="immune-response.html">Immune response</a></li>
<li><a class="" href="primary-secondary.html">Primary &amp; Secondary</a></li>
<li><a class="" href="b-t-cells-macrophages.html">B &amp; T cells, Macrophages</a></li>
<li><a class="" href="genetics-1.html">Genetics</a></li>
<li><a class="" href="immunoglobulins.html">Immunoglobulins</a></li>
<li><a class="" href="classes-subclasses.html">Classes &amp; Subclasses</a></li>
<li><a class="" href="structure.html">Structure</a></li>
<li><a class="" href="properties.html">Properties</a></li>
<li><a class="" href="ag-ab-interactions.html">Ag-Ab Interactions</a></li>
<li><a class="" href="principles.html">Principles</a></li>
<li><a class="" href="testing-1.html">Testing</a></li>
<li><a class="" href="complement.html">Complement</a></li>
<li><a class="" href="pathway-mechanisms.html">Pathway Mechanisms</a></li>
<li><a class="" href="biologic-properties.html">Biologic Properties</a></li>
<li><a class="" href="physiology-pathophysiology.html">Physiology &amp; Pathophysiology</a></li>
<li><a class="" href="blood-physiology.html">Blood Physiology</a></li>
<li><a class="" href="circulation-volume.html">Circulation &amp; Volume</a></li>
<li><a class="" href="composition-function.html">Composition &amp; Function</a></li>
<li><a class="" href="cell-survival.html">Cell Survival</a></li>
<li><a class="" href="cell-metabolism.html">Cell Metabolism</a></li>
<li><a class="" href="hemostasis-coagulation.html">Hemostasis &amp; Coagulation</a></li>
<li><a class="" href="factors-disorders.html">Factors &amp; Disorders</a></li>
<li><a class="" href="plt-functions-disorders.html">PLT Functions &amp; Disorders</a></li>
<li><a class="" href="hdfn.html">HDFN</a></li>
<li><a class="" href="pathophysiology.html">Pathophysiology</a></li>
<li><a class="" href="detection.html">Detection</a></li>
<li><a class="" href="treatment.html">Treatment</a></li>
<li><a class="" href="prevention.html">Prevention</a></li>
<li><a class="" href="cytopenias-1.html">Cytopenias</a></li>
<li><a class="" href="anemia.html">Anemia</a></li>
<li><a class="active" href="thrombocytopenia.html">Thrombocytopenia</a></li>
<li><a class="" href="neutropenia.html">Neutropenia</a></li>
<li><a class="" href="transplantation-1.html">Transplantation</a></li>
<li><a class="" href="solid-organ.html">Solid Organ</a></li>
<li><a class="" href="hpc.html">HPC</a></li>
<li class="book-part">Serology &amp; Molecular</li>
<li><a class="" href="routine-tests.html">Routine Tests</a></li>
<li><a class="" href="blood-grouping.html">Blood Grouping</a></li>
<li><a class="" href="compatibility.html">Compatibility</a></li>
<li><a class="" href="antibody-detection.html">Antibody Detection</a></li>
<li><a class="" href="crossmatch.html">Crossmatch</a></li>
<li><a class="" href="ab-id-significance.html">Ab ID &amp; Significance</a></li>
<li><a class="" href="dat.html">DAT</a></li>
<li><a class="" href="reagents.html">Reagents</a></li>
<li><a class="" href="antiglobulin-sera.html">Antiglobulin Sera</a></li>
<li><a class="" href="blood-grouping-sera.html">Blood Grouping Sera</a></li>
<li><a class="" href="reagent-rbcs.html">Reagent RBCs</a></li>
<li><a class="" href="special-tests-reagents.html">Special Tests &amp; Reagents</a></li>
<li><a class="" href="enzymes.html">Enzymes</a></li>
<li><a class="" href="enhancement-media.html">Enhancement Media</a></li>
<li><a class="" href="lectins.html">Lectins</a></li>
<li><a class="" href="adsorptions.html">Adsorptions</a></li>
<li><a class="" href="elutions.html">Elutions</a></li>
<li><a class="" href="titrations-1.html">Titrations</a></li>
<li><a class="" href="cell-separations.html">Cell Separations</a></li>
<li><a class="" href="elisa.html">ELISA</a></li>
<li><a class="" href="molecular-techniques.html">Molecular Techniques</a></li>
<li><a class="" href="neutralization.html">Neutralization</a></li>
<li><a class="" href="thiol-reagents.html">Thiol Reagents</a></li>
<li><a class="" href="immunofluorescence.html">Immunofluorescence</a></li>
<li><a class="" href="solid-phase.html">Solid Phase</a></li>
<li><a class="" href="column-agglutination.html">Column Agglutination</a></li>
<li><a class="" href="chloroquine-diphosphate.html">Chloroquine Diphosphate</a></li>
<li><a class="" href="edta-glycine-acid.html">EDTA-Glycine Acid</a></li>
<li><a class="" href="quality-assurance.html">Quality Assurance</a></li>
<li><a class="" href="blood-samples.html">Blood Samples</a></li>
<li><a class="" href="reagents-1.html">Reagents</a></li>
<li><a class="" href="test-procedures.html">Test Procedures</a></li>
<li class="book-part">Transfusion Practice</li>
<li><a class="" href="indications.html">Indications</a></li>
<li><a class="" href="component-therapy.html">Component Therapy</a></li>
<li><a class="" href="adverse-effects.html">Adverse Effects</a></li>
<li><a class="" href="immunologic.html">Immunologic</a></li>
<li><a class="" href="nonimmunologic.html">Nonimmunologic</a></li>
<li><a class="" href="ttds.html">TTDs</a></li>
<li><a class="" href="apheresis-extracorporeal-circulation.html">Apheresis &amp; Extracorporeal Circulation</a></li>
<li><a class="" href="blood-administration-patient-blood-management.html">Blood Administration &amp; Patient Blood Management</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="thrombocytopenia" class="section level1 unnumbered">
<h1>Thrombocytopenia<a class="anchor" aria-label="anchor" href="#thrombocytopenia"><i class="fas fa-link"></i></a>
</h1>
<p><strong>Thrombocytopenia</strong> simply means having a lower-than-normal number of platelets circulating in the blood (typically defined as &lt;150,000/µL or &lt;150 x 10<sup>9</sup>/L). Platelets are our tiny “first responders” for stopping bleeding, so when their numbers drop, the primary risk is <strong>bleeding</strong></p>
<p>Just like with anemia, thrombocytopenia isn’t a disease itself but a sign of an underlying issue. We need to figure out <em>why</em> the platelet count is low. The causes fall nicely into <strong>non-immune</strong> and <strong>immune</strong> categories</p>
<div id="non-immune-thrombocytopenia-when-antibodies-arent-the-main-culprit" class="section level2 unnumbered">
<h2>
<strong>Non-Immune Thrombocytopenia: When Antibodies Aren’t the Main Culprit</strong><a class="anchor" aria-label="anchor" href="#non-immune-thrombocytopenia-when-antibodies-arent-the-main-culprit"><i class="fas fa-link"></i></a>
</h2>
<p>These causes involve problems with platelet production, non-antibody-mediated destruction or consumption, or platelets getting stuck somewhere</p>
<div id="pathophysiology-how-it-happens-2" class="section level3 unnumbered">
<h3>
<strong>Pathophysiology (How it Happens)</strong><a class="anchor" aria-label="anchor" href="#pathophysiology-how-it-happens-2"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Decreased Platelet Production:</strong> The bone marrow “factory” isn’t making enough platelets
<ul>
<li>
<strong>Bone Marrow Failure/Suppression</strong>
<ul>
<li>
<em>Aplastic Anemia:</em> Failure of the marrow to produce all cell lines, including megakaryocytes (platelet precursors)</li>
<li>
<em>Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS):</em> Malignant cells infiltrate and crowd out normal marrow elements, including megakaryocytes</li>
<li>
<em>Metastatic Cancer:</em> Cancer cells from elsewhere invade the marrow</li>
<li>
<em>Chemotherapy/Radiation Therapy:</em> These treatments damage rapidly dividing cells, including hematopoietic stem cells and megakaryocytes</li>
<li>
<em>Certain Viral Infections:</em> (e.g., HIV, Hepatitis C, CMV, EBV) can directly suppress marrow production</li>
<li>
<em>Alcohol Toxicity:</em> Chronic heavy alcohol use suppresses marrow function</li>
</ul>
</li>
<li>
<strong>Nutritional Deficiencies:</strong> Severe Vitamin B12 or Folate deficiency can impair DNA synthesis, affecting megakaryocyte maturation and platelet production (often part of pancytopenia in megaloblastic anemia)</li>
<li>
<strong>Inherited Syndromes:</strong> Rare genetic conditions affect megakaryocyte development (e.g., Congenital Amegakaryocytic Thrombocytopenia - CAMT, Thrombocytopenia Absent Radii - TAR syndrome)</li>
</ul>
</li>
<li>
<strong>Increased Platelet Destruction or Consumption (Non-Immune):</strong> Platelets are being used up or destroyed too quickly by mechanisms not primarily involving anti-platelet antibodies
<ul>
<li>
<strong>Disseminated Intravascular Coagulation (DIC):</strong> Widespread, uncontrolled activation of both coagulation and fibrinolysis. Platelets are consumed rapidly in the formation of microthrombi throughout the circulation</li>
<li>
<strong>Thrombotic Microangiopathies (TMAs):</strong> Conditions characterized by platelet aggregation in small blood vessels, leading to consumption and organ damage
<ul>
<li>
<em>Thrombotic Thrombocytopenic Purpura (TTP):</em> Usually due to deficiency (often autoimmune) of the enzyme ADAMTS13, which normally cleaves large von Willebrand Factor (vWF) multimers. Uncleaved large vWF multimers cause spontaneous platelet aggregation in the microvasculature</li>
<li>
<em>Hemolytic Uremic Syndrome (HUS):</em> Often triggered by Shiga toxin-producing bacteria (like E. coli O157:H7). Toxin damages endothelial cells, leading to platelet activation and microthrombi formation, particularly affecting the kidneys</li>
</ul>
</li>
<li>
<strong>Mechanical Destruction:</strong> Physical shearing forces damage platelets (e.g., malfunctioning prosthetic heart valves, extracorporeal circuits like ECMO or cardiopulmonary bypass)</li>
<li>
<strong>Giant Hemangiomas (Kasabach-Merritt Syndrome):</strong> Platelets become trapped and consumed within large vascular tumors</li>
</ul>
</li>
<li>
<strong>Sequestration:</strong> Platelets get pooled or trapped, reducing the number in active circulation
<ul>
<li>
<strong>Hypersplenism:</strong> An enlarged spleen (due to various causes like liver cirrhosis, portal hypertension, lymphoma, infections) traps an excessive proportion of platelets (normally holds ~1/3, can hold up to 90% when enlarged)</li>
</ul>
</li>
</ul>
</div>
<div id="detection-finding-the-cause-1" class="section level3 unnumbered">
<h3>
<strong>Detection (Finding the Cause)</strong><a class="anchor" aria-label="anchor" href="#detection-finding-the-cause-1"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Clinical Assessment:</strong> History (meds, alcohol, infections, bleeding pattern, family history), physical exam (petechiae, purpura, ecchymoses, splenomegaly, signs of underlying disease)</li>
<li>
<strong>Laboratory Tests</strong>
<ul>
<li>
<strong>Complete Blood Count (CBC) with Differential &amp; Platelet Count:</strong> Confirms thrombocytopenia. Check WBC and RBC lines for other cytopenias (pancytopenia suggests marrow failure)</li>
<li>
<strong>Peripheral Blood Smear Review:</strong> <strong>ESSENTIAL!</strong>
<ul>
<li>Confirms low platelet count (visual estimate)</li>
<li>Rules out <strong>pseudothrombocytopenia</strong> (platelet clumping, usually EDTA-dependent artifact - redraw in sodium citrate tube!)</li>
<li>Assesses platelet morphology: Giant platelets (inherited syndromes like Bernard-Soulier, ITP), platelet fragments?</li>
<li>Looks for associated findings: Schistocytes (fragmented RBCs - hallmark of TTP/HUS/DIC), blasts (leukemia), teardrop cells (marrow infiltration), hypersegmented neutrophils (B12/folate deficiency)</li>
</ul>
</li>
<li>
<strong>Coagulation Studies (PT, aPTT, Fibrinogen, D-dimer):</strong> Crucial if DIC is suspected (prolonged PT/aPTT, low fibrinogen, high D-dimer)</li>
<li>
<strong>Liver Function Tests / Renal Function Tests:</strong> Assess for underlying organ disease</li>
<li>
<strong>Bone Marrow Aspirate/Biopsy:</strong> Indicated if decreased production is suspected or the cause remains unclear. Assesses cellularity, presence/morphology of megakaryocytes, infiltrative processes</li>
<li>
<strong>ADAMTS13 Activity:</strong> Specific test for TTP (activity usually &lt;10%)</li>
<li>
<strong>Infectious Disease Testing:</strong> (HIV, HCV, etc., if suspected)</li>
</ul>
</li>
</ul>
</div>
<div id="treatment-6" class="section level3 unnumbered">
<h3>
<strong>Treatment</strong><a class="anchor" aria-label="anchor" href="#treatment-6"><i class="fas fa-link"></i></a>
</h3>
<p>Treatment MUST address the underlying cause:</p>
<ul>
<li>
<strong>Decreased Production:</strong> Treat the underlying condition (e.g., leukemia chemo, B12/folate replacement, stop offending drug/alcohol). Thrombopoietin Receptor Agonists (TPO-RAs like Romiplostim, Eltrombopag) can stimulate platelet production in some settings (e.g., aplastic anemia, chemo-induced). Stem cell transplant for aplastic anemia/leukemia</li>
<li>
<strong>Increased Destruction/Consumption</strong>
<ul>
<li>
<em>DIC:</em> Treat underlying trigger (sepsis, trauma), supportive care with blood components (FFP, Cryo, Platelets)</li>
<li>
<em>TTP:</em> <strong>Plasma Exchange (PEX)</strong> is life-saving! Removes autoantibodies and large vWF multimers, replenishes ADAMTS13. Immunosuppression often added</li>
<li>
<em>HUS:</em> Primarily supportive care (especially renal support). PEX less effective than in TTP. Eculizumab (anti-C5 antibody) for atypical HUS</li>
</ul>
</li>
<li>
<strong>Sequestration:</strong> Treat underlying cause of splenomegaly if possible. Splenectomy is rarely done just for sequestration but may improve counts if done for another reason</li>
<li>
<strong>Platelet Transfusion:</strong> Key supportive measure when counts are critically low (&lt;10-20,000/µL for prophylaxis against spontaneous bleeding) or if the patient has active, significant bleeding. <strong>Transfusion treats the symptom (low count/bleeding), not the cause</strong>
</li>
</ul>
</div>
</div>
<div id="immune-thrombocytopenia-when-the-immune-system-attacks-platelets" class="section level2 unnumbered">
<h2>
<strong>Immune Thrombocytopenia: When the Immune System Attacks Platelets</strong><a class="anchor" aria-label="anchor" href="#immune-thrombocytopenia-when-the-immune-system-attacks-platelets"><i class="fas fa-link"></i></a>
</h2>
<p>Here, antibodies are the primary drivers of platelet destruction</p>
<div id="pathophysiology-how-it-happens-3" class="section level3 unnumbered">
<h3>
<strong>Pathophysiology (How it Happens)</strong><a class="anchor" aria-label="anchor" href="#pathophysiology-how-it-happens-3"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Immune Thrombocytopenia (ITP):</strong> (Formerly Idiopathic Thrombocytopenic Purpura)
<ul>
<li>
<strong>Mechanism:</strong> Autoantibodies (usually <strong>IgG</strong>) are produced against platelet surface glycoproteins (most commonly <strong>GPIIb/IIIa</strong> or <strong>GPIb/IX</strong>). These antibody-coated platelets are recognized by Fc receptors on macrophages, primarily in the <strong>spleen</strong>, leading to premature clearance (<strong>opsonization and phagocytosis</strong>). Some antibodies may also impair megakaryocyte function, contributing to reduced production</li>
<li>
<strong>Types</strong>
<ul>
<li>
<em>Primary ITP:</em> No identifiable underlying cause</li>
<li>
<em>Secondary ITP:</em> Associated with other conditions (e.g., SLE, HIV, HCV, CLL, certain drugs)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Alloimmune Thrombocytopenia:</strong> Antibodies against non-self platelet antigens
<ul>
<li>
<strong>Neonatal Alloimmune Thrombocytopenia (NAIT):</strong> Mother lacks a specific Human Platelet Antigen (HPA, most commonly <strong>HPA-1a</strong>) that the fetus inherits from the father. Mother produces <strong>IgG alloantibodies</strong> against the fetal HPA during pregnancy. These antibodies cross the placenta and destroy fetal/neonatal platelets. Can cause severe thrombocytopenia and risk of intracranial hemorrhage in the fetus/newborn. Analogous to HDFN, but for platelets</li>
<li>
<strong>Post-Transfusion Purpura (PTP):</strong> Rare but serious. Occurs ~1-2 weeks after transfusion. Patients (usually multiparous women negative for HPA-1a) develop high-titer <strong>anti-HPA-1a</strong> (or other HPA antibodies). Paradoxically, these antibodies destroy <em>both</em> transfused antigen-positive platelets <em>and</em> the patient’s own antigen-negative platelets (mechanism unclear, possibly bystander destruction or immune complex formation). Results in sudden, severe thrombocytopenia</li>
</ul>
</li>
<li>
<strong>Drug-Induced Immune Thrombocytopenia (DITP):</strong> (Excluding HIT)
<ul>
<li>
<strong>Mechanism:</strong> Similar to DIHA. Drugs can act as haptens, trigger immune complex formation, or induce drug-dependent antibodies that bind platelet glycoproteins only when the drug is present. Leads to antibody-mediated platelet clearance</li>
<li>
<strong>Common culprits:</strong> Quinine, Quinidine, Sulfonamides, Vancomycin, Rifampin, some NSAIDs</li>
</ul>
</li>
<li>
<strong>Heparin-Induced Thrombocytopenia (HIT):</strong> <strong>(CRITICAL TO RECOGNIZE!)</strong>
<ul>
<li>
<strong>Mechanism:</strong> A specific, dangerous form of DITP. Occurs 5-10 days after heparin exposure (or sooner if prior exposure). Patients develop <strong>IgG antibodies</strong> against complexes of <strong>Platelet Factor 4 (PF4)</strong> (a protein released from platelet alpha granules) and <strong>heparin</strong>
</li>
<li>
<strong>The Paradox:</strong> These PF4-heparin-IgG immune complexes bind to Fc receptors (FcγRIIa) on platelet surfaces, causing <strong>massive platelet activation, aggregation, and degranulation</strong>. This leads to:
<ol style="list-style-type: decimal">
<li>
<strong>Prothrombotic State</strong> Release of procoagulant microparticles and further platelet consumption -&gt; high risk of <strong>venous and arterial thrombosis</strong> (DVT, PE, limb ischemia, stroke, MI)</li>
<li>
<strong>Thrombocytopenia</strong> Activated platelets are rapidly cleared from circulation by the MPS</li>
</ol>
</li>
<li>
<strong>Key Feature:</strong> HIT is primarily a <strong>prothrombotic disorder</strong> where thrombocytopenia is a marker, not necessarily the main clinical problem</li>
</ul>
</li>
</ul>
</div>
<div id="detection-finding-the-immune-cause-1" class="section level3 unnumbered">
<h3>
<strong>Detection (Finding the Immune Cause)</strong><a class="anchor" aria-label="anchor" href="#detection-finding-the-immune-cause-1"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>Clinical Assessment:</strong> History is paramount! (New drugs? Heparin exposure? Recent transfusion/pregnancy? Autoimmune symptoms?). Bleeding pattern (ITP, NAIT, PTP, DITP) vs. Thrombosis (HIT)</li>
<li>
<strong>Laboratory Tests</strong>
<ul>
<li>
<strong>CBC/Smear:</strong> Confirm thrombocytopenia. Rule out pseudothrombocytopenia. Giant platelets common in ITP. Schistocytes should NOT be prominent (if present, consider TTP/HUS/DIC instead or concurrently)</li>
<li>
<strong>ITP Diagnosis:</strong> Primarily a diagnosis of exclusion. Platelet autoantibody testing is generally <strong>not recommended</strong> due to poor sensitivity and specificity</li>
<li>
<strong>NAIT Diagnosis:</strong> Test maternal serum for HPA antibodies; HPA genotype mother, father, and infant (if possible)</li>
<li>
<strong>PTP Diagnosis:</strong> Test patient serum for HPA antibodies (usually anti-HPA-1a)</li>
<li>
<strong>DITP Diagnosis:</strong> Requires high clinical suspicion and temporal association with drug initiation. Drug withdrawal leads to recovery. Specialized testing for drug-dependent antibodies is complex and not widely available</li>
<li>
<strong>HIT Diagnosis:</strong> Requires BOTH clinical suspicion (using scoring systems like the “4Ts”) AND laboratory confirmation:
<ul>
<li>
<em>Immunoassays:</em> Detect antibodies binding to PF4/heparin complexes (e.g., ELISA). High sensitivity but moderate specificity (can be positive without clinical HIT)</li>
<li>
<em>Functional Assays:</em> Detect platelet activation by patient serum in the presence of heparin (e.g., Serotonin Release Assay - SRA, Heparin-Induced Platelet Aggregation - HIPA). High specificity but technically demanding. Considered gold standard</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="treatment-7" class="section level3 unnumbered">
<h3>
<strong>Treatment</strong><a class="anchor" aria-label="anchor" href="#treatment-7"><i class="fas fa-link"></i></a>
</h3>
<ul>
<li>
<strong>ITP</strong>
<ul>
<li>
<strong>Goal:</strong> Raise platelet count to a safe level (prevent major bleeding), not necessarily normalize it</li>
<li>
<strong>First-line:</strong> Corticosteroids (suppress antibody production/clearance), Intravenous Immune Globulin (IVIg - rapidly blocks Fc receptors on macrophages, temporary effect)</li>
<li>
<strong>Second-line:</strong> Rituximab (anti-CD20, depletes B cells), TPO-RAs, Splenectomy (removes primary site of destruction and some antibody production), other immunosuppressants</li>
<li>
<strong>Platelet Transfusion:</strong> Generally reserved for life-threatening bleeding, as transfused platelets are rapidly destroyed</li>
</ul>
</li>
<li>
<strong>NAIT</strong>
<ul>
<li>
<strong>Antenatal:</strong> If diagnosed prenatally in high-risk cases: Maternal IVIg +/- steroids</li>
<li>
<strong>Postnatal:</strong> <strong>HPA-matched platelets</strong> (e.g., HPA-1a negative platelets if mother has anti-HPA-1a) are ideal but often unavailable emergently. <strong>Washed, irradiated maternal platelets</strong> are an alternative. IVIg for the infant. Exchange transfusion rarely needed</li>
</ul>
</li>
<li>
<strong>PTP</strong>
<ul>
<li>
<strong>First-line:</strong> <strong>IVIg</strong>. Plasma exchange may be considered</li>
<li>
<strong>Platelet Transfusion:</strong> Generally avoided unless life-threatening bleeding. If needed, <strong>HPA-matched platelets</strong> (e.g., HPA-1a negative) are required</li>
</ul>
</li>
<li>
<strong>DITP</strong>
<ul>
<li>
<strong>STOP THE OFFENDING DRUG!:</strong> Platelet count usually recovers within days to weeks</li>
<li>Supportive care, platelet transfusion only if severe bleeding</li>
</ul>
</li>
<li>
<strong>HIT</strong>
<ul>
<li>
<strong>STOP ALL HEPARIN EXPOSURE IMMEDIATELY:</strong> (including flushes, coated catheters)!</li>
<li>
<strong>Initiate a non-heparin anticoagulant:</strong> (e.g., Direct Thrombin Inhibitors like Argatroban or Bivalirudin; Fondaparinux in some cases) even if thrombosis is not yet evident</li>
<li>
<strong>DO NOT TRANSFUSE PLATELETS routinely,:</strong> as this may “fuel the fire” and increase thrombotic risk. Only consider for life-threatening hemorrhage</li>
</ul>
</li>
</ul>
</div>
</div>
<div id="key-terms-68" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-68"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Thrombocytopenia:</strong> Low platelet count (&lt;150,000/µL)</li>
<li>
<strong>Megakaryocyte:</strong> Large bone marrow cell from which platelets bud off</li>
<li>
<strong>Pseudothrombocytopenia:</strong> Artificially low platelet count on automated analyzers due to <em>in vitro</em> platelet clumping (usually EDTA-dependent)</li>
<li>
<strong>Petechiae:</strong> Pinpoint skin hemorrhages characteristic of low platelets</li>
<li>
<strong>Purpura:</strong> Larger bruises/skin hemorrhages</li>
<li>
<strong>Sequestration:</strong> Trapping of platelets, typically in an enlarged spleen (hypersplenism)</li>
<li>
<strong>Disseminated Intravascular Coagulation (DIC):</strong> Pathological widespread activation of clotting and fibrinolysis, consuming platelets and factors</li>
<li>
<strong>Thrombotic Thrombocytopenic Purpura (TTP):</strong> TMA usually due to ADAMTS13 deficiency, causing microthrombi</li>
<li>
<strong>Hemolytic Uremic Syndrome (HUS):</strong> TMA often toxin-induced, causing microthrombi, primarily affecting kidneys</li>
<li>
<strong>Immune Thrombocytopenia (ITP):</strong> Autoimmune disorder with antibodies targeting platelet glycoproteins</li>
<li>
<strong>Neonatal Alloimmune Thrombocytopenia (NAIT):</strong> Alloimmune disorder where maternal IgG antibodies target fetal platelet antigens</li>
<li>
<strong>Post-Transfusion Purpura (PTP):</strong> Alloimmune disorder where antibodies develop post-transfusion, destroying transfused and autologous platelets</li>
<li>
<strong>Heparin-Induced Thrombocytopenia (HIT):</strong> Prothrombotic disorder caused by antibodies to PF4/heparin complexes, leading to platelet activation and consumption</li>
<li>
<strong>Human Platelet Antigens (HPAs):</strong> Polymorphic antigens expressed on platelet glycoproteins, targets in NAIT/PTP</li>
<li>
<strong>Platelet Factor 4 (PF4):</strong> Protein released from platelet alpha granules, target antigen in HIT</li>
<li>
<strong>Plasma Exchange (PEX):</strong> Therapeutic procedure to remove patient plasma and replace it with donor plasma or albumin</li>
<li>
<strong>Intravenous Immune Globulin (IVIg):</strong> Concentrated human IgG used to treat various immune cytopenias</li>
<li>
<strong>Thrombopoietin Receptor Agonists (TPO-RAs):</strong> Drugs that stimulate platelet production by mimicking thrombopoietin</li>
</ul>
</div>
</div>
<!-- Scoll to TOC element -->
<script defer>
  // adjust TOC scroll to selected element/topic
  function scroll_to_element() {
    header_height = document.getElementsByTagName('header')[0].offsetHeight/2;
    toc_element_position = document.querySelector('.book-toc > li > a.active').offsetTop;
    if(document.querySelector('.book-toc > li > a.active').offsetLeft == 0) {
      toc_element_position1 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetTop;
      toc_element_position2 = document.querySelector('.book-toc > li > a.active').offsetParent.offsetHeight;
      toc_element_position = toc_element_position1 + toc_element_position2;
    }
    document.getElementsByTagName('header')[0].scrollTo(0, toc_element_position - header_height, 'smooth');
  }
  window.onload = scroll_to_element();

  // hide those labes that take up multiple lines
  sections = [];
  topics = [];
  function hide_label() {
    // sections
    document
      .querySelectorAll('.book-toc > li')
      .forEach(elem => {
        window
          .getComputedStyle(elem)
          .textTransform === "uppercase"
          &&
          elem.classList
          .contains('book-part')
          ? sections.push(elem)
          : '';
      });

    // topics
    document
      .querySelectorAll('.book-toc > li')
      .forEach(elem => {
        window
          .getComputedStyle(elem)
          .textTransform === "uppercase"
          &&
          !elem.classList
          .contains('book-part')
          ? topics.push(elem)
          : '';
      });
  }
  hide_label();
  head = document.getElementsByTagName('header')[0];
  head.addEventListener('scroll', () => {
    // sections
    count_sections = 0;
    prev_sections_elem = '';
    sections
      .forEach((elem) => {
      if(count_sections === 0) {
        initial_y = elem.getBoundingClientRect().y + 20;
        count_sections = 1;
      } else {
        if(elem.getBoundingClientRect().y < initial_y) {
          prev_sections_elem.classList.add('hide_label');
        } else {
          prev_sections_elem.classList.remove('hide_label');
        }
      }
      prev_sections_elem = elem;
    });
    // topics
    count_topics = 0;
    prev_topic_elem = '';
    topics
      .forEach((elem) => {
      if(count_topics === 0) {
        initial_y = elem.getBoundingClientRect().y + 20;
        count_topics = 1;
      } else {
        if(elem.getBoundingClientRect().y < initial_y) {
          prev_topic_elem.classList.add('hide_label');
        } else {
          prev_topic_elem.classList.remove('hide_label');
        }
      }
      prev_topic_elem = elem;
    });
  });
</script><div class="chapter-nav">
<div class="prev"><a href="anemia.html">Anemia</a></div>
<div class="next"><a href="neutropenia.html">Neutropenia</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#thrombocytopenia">Thrombocytopenia</a></li>
<li>
<a class="nav-link" href="#non-immune-thrombocytopenia-when-antibodies-arent-the-main-culprit">Non-Immune Thrombocytopenia: When Antibodies Aren’t the Main Culprit</a><ul class="nav navbar-nav">
<li><a class="nav-link" href="#pathophysiology-how-it-happens-2">Pathophysiology (How it Happens)</a></li>
<li><a class="nav-link" href="#detection-finding-the-cause-1">Detection (Finding the Cause)</a></li>
<li><a class="nav-link" href="#treatment-6">Treatment</a></li>
</ul>
</li>
<li>
<a class="nav-link" href="#immune-thrombocytopenia-when-the-immune-system-attacks-platelets">Immune Thrombocytopenia: When the Immune System Attacks Platelets</a><ul class="nav navbar-nav">
<li><a class="nav-link" href="#pathophysiology-how-it-happens-3">Pathophysiology (How it Happens)</a></li>
<li><a class="nav-link" href="#detection-finding-the-immune-cause-1">Detection (Finding the Immune Cause)</a></li>
<li><a class="nav-link" href="#treatment-7">Treatment</a></li>
</ul>
</li>
<li><a class="nav-link" href="#key-terms-68">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob/blob/main/Rmd/03-B-04-b.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Blood-Bank/blob/edit/main/Rmd/03-B-04-b.Rmd" target="_blank">Edit this page <i class="fab fa-github"></i></a></li>
          <li><a id="buymeacoffee" href="https://buymeacoffee.com/bloodcellid" target="_blank">NEED Caffeine</a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->


</body>
</html>
